PHOTOCURE - REPURCHASE PROGRAM OF OWN SHARES

2/7/2013 11:23 AM EST

Oslo, Norway, 7 February 2013: Photocure ASA has 
today purchased 2735 own shares in the market at an 
average price of NOK 37.4828 per share. After this 
transaction, Photocure owns a total of 216,284 own 
shares.
 
The transaction is part of share repurchase program, 
authorized by the Annual General Meeting held on 10 
May 2012 in connection with employee share purchase 
program. In accordance with the resolution, the Board 
of Directors of Photocure ASA has decided to acquire 
up to 100 000 shares. For more details on the 
program, please download the minutes under Investor 
relations/Reports and presentations at 
www.photocure.com.
 
 
For further information contact:
Photocure
Erik Dahl, CFO
Tel: + 47 450 55 000, Email:   
 
About Photocure
Photocure, headquartered in Oslo Norway, is a 
specialty pharmaceutical company and world leader in 
photodynamic technology. Based on our unique 
proprietary Photocure Technology platform, Photocure 
develops and commercializes highly selective and 
effective solutions within disease areas with high 
unmet medical need, such as bladder cancer, HPV and 
precancerous cervical lesions, colorectal cancer and 
skin conditions. Our aim is to provide solutions 
which can improve health outcomes for patients 
worldwide. Photocure is listed on the Oslo Stock 
Exchange (OSE: PHO). Information about Photocure is 
available at www.photocure.com.
 
Photodynamic technology is the application of a 
photosensitizer followed by exposure to light for 
activation.
HPV: human papilloma virus
Photocure Technology is Photocure's specifically 
designed photosensitizers combined with the exposure 
to light for diagnosis and/or treatment of specific 
conditions. 
All trademarks mentioned in this release are 
protected by law and registered trademarks of 
Photocure.
 
This information is subject of the disclosure 
requirements acc. to §5-12 vphl (Norwegian Securities 
Trading Act)